IRWD
Ironwood Pharmaceuticals, Inc. NASDAQ Listed Feb 3, 2010$4.17
Mkt Cap $680.0M
52w Low $0.53
69.3% of range
52w High $5.78
50d MA $3.73
200d MA $2.87
P/E (TTM)
29.6x
EV/EBITDA
8.9x
P/B
—
Debt/Equity
-2.3x
ROE
0.9%
P/FCF
4.3x
RSI (14)
—
ATR (14)
—
Beta
0.17
50d MA
$3.73
200d MA
$2.87
Avg Volume
2.8M
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
100 Summer Street · Boston, MA 02110 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 4.83 | -3.1% | -13.7% | — | — | — | — | — |
| Feb 25, 2026 | AMC | 0.02 | -0.01 | -150.0% | 3.36 | +3.9% | +8.9% | +1.8% | +6.2% | +8.3% | +11.3% | — |
| Nov 10, 2025 | AMC | 0.09 | 0.24 | +166.7% | 2.53 | -1.2% | +14.2% | +22.9% | +33.2% | +24.1% | +23.7% | — |
| Aug 7, 2025 | AMC | -0.02 | 0.14 | +800.0% | 0.88 | +0.0% | +1.9% | -5.0% | +11.6% | +23.9% | +21.6% | — |
| May 7, 2025 | AMC | -0.05 | -0.14 | -180.0% | 0.79 | -2.4% | -11.6% | -10.5% | -7.3% | -13.6% | -18.1% | — |
| Feb 27, 2025 | AMC | 0.10 | 0.02 | -80.0% | 1.62 | +0.6% | -0.6% | -6.2% | -8.0% | -4.9% | -4.3% | — |
| Nov 7, 2024 | AMC | 0.08 | 0.02 | -75.0% | 4.66 | +1.3% | +6.4% | +2.6% | -5.8% | -7.5% | -11.8% | — |
| Aug 8, 2024 | AMC | 0.15 | -0.01 | -103.6% | 4.05 | +2.0% | +4.7% | +4.7% | +10.9% | +7.2% | +9.9% | — |
| May 9, 2024 | AMC | 0.18 | -0.02 | -111.1% | 6.74 | +1.0% | +3.9% | -0.7% | -1.6% | -2.7% | -1.5% | — |
| Feb 15, 2024 | AMC | 0.21 | -0.01 | -104.8% | 14.99 | -0.1% | -2.7% | -1.1% | +1.0% | -0.9% | +0.5% | — |
| Nov 9, 2023 | AMC | 0.16 | 0.09 | -43.8% | 9.52 | +1.6% | +2.3% | -1.4% | +2.4% | +2.5% | -0.8% | — |
| Aug 8, 2023 | AMC | 0.25 | 0.31 | +24.0% | 10.31 | +0.0% | -6.8% | -5.8% | -2.3% | -2.8% | -4.4% | — |
| May 4, 2023 | AMC | 0.24 | 0.25 | +4.2% | 10.58 | +0.9% | +0.9% | -0.7% | -3.0% | -1.5% | -3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 | Citizens | Maintains | Market Outperform → Market Outperform | — | $3.36 | $3.49 | +3.9% | +8.9% | +1.8% | +6.2% | +8.3% | +11.3% |
| Jan 5 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $4.27 | $4.51 | +5.6% | +7.5% | +0.7% | -4.4% | -6.8% | -4.9% |
| Jan 5 | Citizens | Upgrade | Market Perform → Market Outperform | — | $4.27 | $4.51 | +5.6% | +7.5% | +0.7% | -4.4% | -6.8% | -4.9% |
| Nov 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $2.53 | $2.50 | -1.2% | +14.2% | +22.9% | +33.2% | +24.1% | +23.7% |
| Apr 15 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $0.65 | $0.61 | -5.4% | +11.5% | +15.8% | +12.2% | +8.8% | +11.0% |
| Apr 15 | Jefferies | Downgrade | Buy → Hold | — | $0.65 | $0.61 | -5.4% | +11.5% | +15.8% | +12.2% | +8.8% | +11.0% |
| Apr 14 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $0.95 | $0.70 | -26.4% | -31.5% | -23.6% | -20.7% | -23.1% | -25.4% |
| Jan 30 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.72 | $3.30 | -11.3% | -38.2% | -37.1% | -43.5% | -41.4% | -43.3% |
| Jan 22 | Craig-Hallum | Maintains | Buy → Buy | — | $3.79 | $3.75 | -1.1% | -1.8% | -0.5% | -2.1% | +0.3% | +0.3% |
| Aug 9 | Wells Fargo | Maintains | Overweight → Overweight | — | $4.05 | $4.13 | +2.0% | +4.7% | +4.7% | +10.9% | +7.2% | +9.9% |
| Aug 9 | Craig-Hallum | Maintains | Buy → Buy | — | $4.05 | $4.13 | +2.0% | +4.7% | +4.7% | +10.9% | +7.2% | +9.9% |
| May 10 | Craig-Hallum | Maintains | Buy → Buy | — | $6.74 | $6.81 | +1.0% | +3.9% | -0.7% | -1.6% | -2.7% | -1.5% |
| Mar 1 | Wells Fargo | Maintains | Overweight → Overweight | — | $9.43 | $9.29 | -1.5% | -3.8% | -1.1% | -1.2% | -8.6% | -5.3% |
| Feb 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $14.99 | $14.97 | -0.1% | -2.7% | -1.1% | +1.0% | -0.9% | +0.5% |
| May 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.85 | $11.00 | +1.4% | +1.1% | -0.4% | -1.1% | -0.4% | -0.9% |
| Aug 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $11.14 | $11.15 | +0.1% | -2.2% | -2.5% | -3.4% | -2.8% | -2.3% |
| Aug 16 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $11.91 | $12.02 | +0.9% | +0.8% | -1.7% | -0.5% | +0.2% | -2.9% |
| Apr 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $11.78 | $11.98 | +1.7% | +3.4% | +3.4% | +0.3% | +0.9% | +0.9% |
| Oct 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $13.77 | $13.83 | +0.4% | +0.6% | -1.6% | -0.9% | -0.8% | -2.6% |
| Jul 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $12.57 | $12.65 | +0.6% | -0.6% | +0.2% | +2.2% | +5.5% | +3.3% |
| Feb 22 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.54 | $9.54 | +0.0% | -1.9% | -0.6% | -2.5% | -5.2% | -3.2% |
| Feb 19 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.32 | $9.34 | +0.2% | +2.4% | +0.4% | +1.7% | -0.2% | -3.0% |
| Nov 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.01 | $10.57 | +5.6% | +6.6% | +7.6% | +15.1% | +15.5% | +15.5% |
| Nov 6 | Credit Suisse | Maintains | Neutral → Neutral | — | $10.01 | $10.57 | +5.6% | +6.6% | +7.6% | +15.1% | +15.5% | +15.5% |
| Sep 30 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $9.42 | $8.96 | -4.9% | -4.5% | -1.5% | -1.2% | -0.6% | +0.8% |
| Aug 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.09 | $10.09 | +0.0% | +1.1% | +0.8% | -1.6% | +0.4% | +1.4% |
| Jul 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.22 | $10.36 | +1.4% | +1.2% | +0.2% | +1.3% | +3.7% | -3.5% |
| Jun 1 | Credit Suisse | Maintains | Neutral → Neutral | — | $9.73 | $9.73 | +0.0% | -0.1% | +7.5% | +3.3% | +0.6% | +2.2% |
| May 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $10.19 | $10.03 | -1.6% | +5.6% | +5.0% | +3.5% | +6.0% | +9.2% |
| May 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.40 | $10.30 | -1.0% | -2.3% | -2.0% | +3.5% | +2.9% | +1.4% |
| Apr 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $10.23 | $10.09 | -1.4% | -2.2% | -5.8% | -0.3% | +2.6% | +1.7% |
| Apr 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $10.58 | $10.28 | -2.8% | -5.4% | -4.3% | -2.5% | -2.6% | -4.5% |
| Mar 27 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $13.29 | $13.49 | +1.5% | -4.0% | -4.3% | +1.8% | +5.5% | -7.4% |
| Feb 25 | HC Wainwright & Co. | Upgrade | Sell → Neutral | — | $14.25 | $14.43 | +1.3% | +1.8% | -1.2% | +1.2% | -0.1% | +3.9% |
| Feb 25 | H.C. Wainwright | Upgrade | Sell → Neutral | — | $14.25 | $14.43 | +1.3% | +1.8% | -1.2% | +1.2% | -0.1% | +3.9% |
| Jan 24 | JP Morgan | Upgrade | Underweight → Neutral | — | $12.42 | $13.00 | +4.7% | +0.6% | +3.5% | +0.0% | +3.9% | +7.1% |
| Nov 7 | JP Morgan | Downgrade | Neutral → Underweight | — | $12.78 | $12.32 | -3.6% | -6.7% | -5.5% | -7.0% | -11.8% | -10.5% |
| Nov 6 | Credit Suisse | Downgrade | Outperform → Neutral | — | $14.13 | $13.50 | -4.5% | -9.6% | -15.6% | -14.5% | -15.9% | -20.2% |
| Aug 9 | Wells Fargo | Maintains | Outperform → Outperform | — | $18.97 | $19.08 | +0.6% | +1.3% | -0.8% | +0.0% | -0.6% | -2.0% |
| Jul 23 | H.C. Wainwright | Maintains | Sell → Sell | — | $20.02 | $19.75 | -1.3% | -0.2% | -2.1% | -4.3% | -5.1% | -7.7% |
| Jul 18 | Cowen & Co. | Downgrade | Outperform → Market Perform | — | $21.07 | $20.23 | -4.0% | -5.6% | -4.8% | -5.0% | -5.2% | -7.0% |
| May 31 | Wells Fargo | Maintains | Outperform → Outperform | — | $17.41 | $17.61 | +1.1% | +6.7% | +5.5% | +2.0% | +0.2% | +2.6% |
| May 9 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $18.38 | $17.36 | -5.5% | -4.5% | -3.4% | +0.9% | +0.8% | -0.4% |
| May 3 | Barclays | Maintains | Equal Weight → Equal Weight | — | $18.91 | $18.79 | -0.6% | -3.0% | -1.7% | -5.0% | -2.8% | -7.2% |
| May 2 | Mizuho | Upgrade | Neutral → Buy | — | $18.69 | $19.11 | +2.2% | +1.2% | -1.8% | -0.5% | -3.9% | -1.7% |
| Jan 5 | Bank of America | Downgrade | Buy → Underperform | — | $15.20 | $14.56 | -4.2% | -0.4% | -5.9% | -6.8% | -8.9% | -0.7% |
| Jan 5 | BofA Securities | Downgrade | Buy → Underperform | — | $15.20 | $14.56 | -4.2% | -0.4% | -5.9% | -6.8% | -8.9% | -0.7% |
| Dec 6 | Mizuho | Downgrade | Buy → Neutral | — | $15.80 | $15.17 | -4.0% | -4.3% | -4.5% | -2.0% | -3.1% | -1.2% |
| Nov 27 | Credit Suisse | Maintains | Outperform → Outperform | — | $15.64 | $15.84 | +1.3% | +3.8% | +6.2% | +9.5% | +10.4% | +10.7% |
| Jul 21 | JP Morgan | Downgrade | Overweight → Neutral | — | $17.00 | $17.00 | +0.0% | +1.3% | +0.6% | +0.2% | +0.6% | -2.1% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
I cannot provide a meaningful analysis because the filing summary contains only technical metadata and schema references with no actual business information about Irwood (IRWD).
Mar 11
8-K
Ironwood Pharmaceuticals, Inc. - Class A -- 8-K Filing
Ironwood Pharmaceuticals raised 2026 guidance to $1.125-$1.175 billion in net sales and over $300 million adjusted EBITDA, while advancing apraglutide Phase 3 trials for short bowel syndrome beginning Q2 2026.
Feb 25
Data updated apr 25, 2026 4:18pm
· Source: massive.com